Acebutolol - CAS 37517-30-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Acebutolol
Catalog Number:
37517-30-9
Synonyms:
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;
CAS Number:
37517-30-9
Description:
Acebutolol is a synthetic butyranilide derivative with hypotensive and antiarrhythmic activity as a beta blocker for the treatment of hypertension and arrhythmias.
Molecular Weight:
336.43
Molecular Formula:
C18H28N2O4
Quantity:
Grams-Kilos
Quality Standard:
Enterprise standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
InChI:
1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
InChIKey:
GOEMGAFJFRBGGG-UHFFFAOYSA-N
Targets:
Others
Chemical Structure
CAS 37517-30-9 Acebutolol

Related Products


CAS 155521-46-3 Alisol G

Alisol G
(CAS: 155521-46-3)

Alisol G, a triterpenoid isolated from the rhizome of Alisma orientale, has hCE2 inhibitory effects.

CAS 86541-74-4 Benazepril HCl

Benazepril HCl
(CAS: 86541-74-4)

Benazepril is a drug of the angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure.

CAS 209467-52-7 Ceftobiprole

Ceftobiprole
(CAS: 209467-52-7)

Ceftobiprole is a cephalosporin prodrug with potent bactericidal activity against methicillin-resistant MRSA and penicillin-resistant Streptococcus pneumoniae (...

CAS 130405-40-2 (-)-Catechin gallate

(-)-Catechin gallate
(CAS: 130405-40-2)

(-)-catechin gallate, an antioxidant component existing in green tea, has been found to be probably effective in restraining tyrosine phosphorylation caused by ...

CAS 86-34-0 phensuximide

phensuximide
(CAS: 86-34-0)

Phensuximide is an anticonvulsant drug. It can be used for the treatment of neurological disorders stemming from the brain. Phensuximide can suppress the paroxy...

ASP-1645
(CAS: 1347392-70-4)

ASP-1645 is a novel P2Y12 receptor antagonist using as an antiplatelet agent.

CAS 67416-61-9 AKBA

AKBA
(CAS: 67416-61-9)

AKBA is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.

CAS 820957-38-8 Retosiban

Retosiban
(CAS: 820957-38-8)

Retosiban is a oxytocin receptor antagonist. It was developed by GlaxoSmithKline for the treatment of preterm labour. Retosiban has high affinity for the oxytoc...

CAS 35543-24-9 Buflomedil Hydrochloride

Buflomedil Hydrochloride
(CAS: 35543-24-9)

Buflomedil HCl is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease.

CAS 4754-39-6 Deoxyadenosine

Deoxyadenosine
(CAS: 4754-39-6)

Deoxyadenosine is a substrate of bacterial methylthioadenosine/S-adenosylhomocysteine (MTA/SAH) nucleosidase and a product inhibitor produced by radical SAM enz...

CAS 34080-08-5 (20S)-Protopanaxatriol

(20S)-Protopanaxatriol
(CAS: 34080-08-5)

20S-Protopanaxatriol (g-PPT), a dammarane-type tetracyclic terpene sapogenin, may be used to study its binding to and modulation of cell function via glucocorto...

CAS 148554-65-8 seco Rapamycin Sodium Salt

seco Rapamycin Sodium Salt
(CAS: 148554-65-8)

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin which is a natural macrolide immunosuppressant. Seco-rapamycin inhibits the ChT-L (D) and ...

CAS 501-68-8 Beclamide

Beclamide
(CAS: 501-68-8)

Beclamide is a chlorinated benzylpropanamide that possesses anticonvulsant activity, has been used for the treatment of tonic-clonic seizyres and has sedative p...

FR295389 sulfuric acid
(CAS: 1019207-72-7)

FR295389 sulfuric acid is the sulfate form of FR295389, which is a new cephalosporin. It has effective in vitro antibacterial activity against metallo-beta-lact...

CAS 77-52-1 Ursolic acid

Ursolic acid
(CAS: 77-52-1)

Ursolic acid is a natural pentacyclic triterpenoid carboxylic acid. It exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.

CAS 299-28-5 Gluconate Calcium

Gluconate Calcium
(CAS: 299-28-5)

Gluconate Calcium is an calcium supplement used in crop pesticide formulations and also in the treatment of too little calcium in the blood.

CAS 112111-44-1 (S)-(+)-Modafinic acid

(S)-(+)-Modafinic acid
(CAS: 112111-44-1)

(S)-(+)-Modafinic acid is the major metabolite of Modafinil(HY-10521A), which is a central nervous system vigilance promoting agent, which posseses neuroprotect...

CH 402
(CAS: 75903-70-7)

CH 402 can inhibit lipid peroxidation.

CAS 1146-98-1 Bromindione

Bromindione
(CAS: 1146-98-1)

Bromindione, an inandione derivative, could be used as an orally bioavaliable anticoagulant.

CAS 94-20-2 Chlorpropamide

Chlorpropamide
(CAS: 94-20-2)

Chlorpropamide is a drug in the sulfonylurea class used to treat type 2 diabetes mellitus. It is a long-acting 1st generation sulfonylurea.

Reference Reading


1.Aqueous chlorination of acebutolol: kinetics, transformation by-products, and mechanism.
Khalit WN1, Tay KS2. Environ Sci Pollut Res Int. 2016 Feb;23(3):2521-9. doi: 10.1007/s11356-015-5470-y. Epub 2015 Oct 1.
This study investigated the reaction kinetics and the transformation by-products of acebutolol during aqueous chlorination. Acebutolol is one of the commonly used β-blockers for the treatment of cardiovascular diseases. It has been frequently detected in the aquatic environment. In the kinetics study, the second-order rate constant for the reaction between acebutolol and chlorine (k app) was determined at 25 ± 0.1 °C. The degradation of acebutolol by free available chlorine was highly pH dependence. When the pH increased from 6 to 8, it was found that the k app for the reaction between acebutolol and free available chlorine was increased from 1.68 to 11.2 M(-1) min(-1). By comparing with the reported k app values, the reactivity of acebutolol toward free available chlorine was found to be higher than atenolol and metoprolol but lower than nadolol and propranolol. Characterization of the transformation by-products formed during the chlorination of acebutolol was carried out using liquid chromatography-quadrupole time-of-flight high-resolution mass spectrometry.
2.Identification of Radiodegradation Products of Acebutolol and Alprenolol by HPLC/MS/MS.
Ogrodowczyk M1, Dettlaff K, Kachlicki P, Marciniec B. J AOAC Int. 2015 Jan-Feb;98(1):46-50. doi: 10.5740/jaoacint.14-096.
Two therapeutically active compounds from the group of β-blockers, acebutolol (AC) and alprenolol (AL), in solid form were subjected to ionizing radiation emitted by a beam of high energy electrons from an accelerator with a standard sterilization dose of 25 kGy and in higher doses of 50-400 kGy. The effects of irradiation were detected by chromatographic methods (TLC, HPLC) and a hyphenated method (HPLC/MS/MS). No significant changes in the physicochemical properties of both compounds studied irradiated with 25 kGy were noted, but upon irradiation with the highest dose (400 kGy) the loss of AC and AL content determined by HPLC was 2.79 and 9.12%, respectively. The product of AC decomposition and the two products of AL decomposition were separated and identified by HPLC/MS/MS. It has been established that radiodegradation of AC and AL takes place by oxidation, leading to formation of the products of radiolysis, most probably alcohol derivatives of the β-blockers studied.
3.First Case Report of Smith-Magenis Syndrome (SMS) Among the Arab Community in Nazareth: View and Overview.
Nijim Y1, Adawi A, Bisharat B, Bowirrat A. Medicine (Baltimore). 2016 Jan;95(3):e2362. doi: 10.1097/MD.0000000000002362.
Smith-Magenis syndrome (SMS0) is a complex and rare genetic multisystem disorder characterized by a variable pattern of cognitive deficits accompanied by a1 distinctive behavioral phenotype. SMS is characterized by subtle facial dysmorphology, short stature, sleep disturbances, and neurobehavioral abnormalities. Little is known about the manifestation of his unique case among Arab population and its strategic treatment.This study comes to present a case of SMS in an Arab newborn male who was born in spontaneous delivery on June 29, 2015, with tachypnea, tracheomalacia, and mild hypotonia. The newborn was admitted on the Neonatal Intensive Care Unit (NICU), and various laboratory examinations and clinical examinations were performed.Throughout his hospitalization, feeding difficulties appeared and thus a peripheral venous catheter was inserted in the left leg.After 22 days of follow-up and hospitalizations, the patient status improved and he was discharged with recommendations to be in follow up in pediatric outpatient clinic.
4.Development of SPME-LC-MS method for screening of eight beta-blockers and bronchodilators in plasma and urine samples.
Goryński K1, Kiedrowicz A2, Bojko B3. J Pharm Biomed Anal. 2016 Mar 4. pii: S0731-7085(16)30119-4. doi: 10.1016/j.jpba.2016.03.001. [Epub ahead of print]
The current work describes the development and validation of a simple, efficient, and fast method using solid phase microextraction coupled to liquid chromatography-tandem mass spectrometry (SPME-LC-MS/MS) for the concomitant measurement of eight beta-blockers and bronchodilators in plasma and urine. The presented assay enables quantitative determination of acebutolol, atenolol, fenoterol, nadolol, pindolol, procaterol, sotalol, and timolol. In this work, samples were prepared on a high-throughput platform using the 96-well plate format of the thin film solid phase microextraction (TFME) system, and a biocompatible extraction phase made of hydrophilic-lipophilic balance particles. Analytes were separated on a pentafluorophenyl column (100mm×2.1mm, 3μm) by gradient elution using an UPLC Nexera coupled with an LCMS-8060 mass spectrometer. The mobile phase consisted of water-acetonitrile (0.1% formic acid) at a flow rate of 0.4mLmin-1. The linearity of the method was checked within therapeutic blood-plasma concentrations, and shown to adequately reflect typically expected concentrations of future study samples.